Loading…
KALA BIO, Inc. is projected to decline to $1.06 by 2027, a -10% move from its current price of $1.18. KALA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.08 | $1.17 | $1.27 | -0.09% |
| Jul 14 | $1.04 | $1.17 | $1.32 | -0.19% |
| Jul 15 | $1.02 | $1.17 | $1.35 | -0.28% |
| Jul 16 | $0.9929 | $1.17 | $1.38 | -0.38% |
| Jul 17 | $0.9729 | $1.17 | $1.41 | -0.47% |
| Jul 18 | $0.955 | $1.17 | $1.43 | -0.57% |
| Jul 19 | $0.9388 | $1.17 | $1.45 | -0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9388 | $1.17 | $1.45 | -0.66% |
| Week 2 | $0.8522 | $1.16 | $1.58 | -1.31% |
| Week 3 | $0.79 | $1.15 | $1.68 | -1.97% |
| Week 4 | $0.7403 | $1.14 | $1.77 | -2.61% |
| Week 5 | $0.6985 | $1.14 | $1.85 | -3.25% |
| Week 6 | $0.6624 | $1.13 | $1.93 | -3.89% |
| Week 7 | $0.6305 | $1.12 | $2.00 | -4.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
KALA BIO, Inc. is a healthcare company that develops an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies and was formerly known as Kala Pharmaceuticals, Inc., changing its name to KALA BIO, Inc. in August 2023.
Kala Bio was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc. trades under the symbol KALA and is currently priced at $1.18 with a market capitalization of $21.84M, ranking 4843 by market cap. The stock sits in a niche healthcare/biopharma segment and carries a low current price relative to historical pricing in this listing universe.
The multi-year forecast provides a path of evolving values, with 2026–2027 staying near the current level before turning more bullish in the late 2020s. Notably, 2029–2050 show rising average prices and meaningful ROIs, culminating in a 2050 average of $4.04 with a max of $9.30 and a 244.2% ROI. These projections imply a potential high-end upside, contingent on market and company-specific factors aligning with the forecast.
These figures are estimates and not guarantees. They reflect the provided forecast data and are subject to uncertainty and real-world constraints.”
A major floor 0.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 207.2% above — a clean break opens room to run.
A major ceiling 1453.2% above — clearing it would confirm fresh momentum.
Key KALA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KALA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.39 | Sell | $1.41 | Sell |
| MA 10 | $1.68 | Sell | $1.69 | Sell |
| MA 20 | $2.32 | Sell | $2.08 | Sell |
| MA 50 | $2.87 | Sell | $4.12 | Sell |
| MA 100 | $7.75 | Sell | $17.94 | Sell |
| MA 200 | $41.55 | Sell | $69.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.52 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -115.30 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -62.34 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.04 | Sell |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 10.63 | Buy |
| Momentum (10) | -1.38 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.21 | Sell |
| ADX (14) | 34.99 | Sell |
| ATR (14) | 0.20 | Info |
The 30-day technical picture shows a neutral stance with a cautious setup. The sentiment is NEUTRAL, and the 14-day RSI is 30, suggesting limited upside momentum in the near term. The stock is trading relative to major averages with SMA50 at $2.87 and SMA200 at $41.55, indicating a wide gap between short- and long-term trends.
Support is identified at $1.17 and resistance at $3.61, framing a shallow near-term corridor. Over the last 30 days, the price range has been between $0.683 and $2.02, suggesting limited upside within this window. The annualized volatility stands at 200%, underscoring elevated risk and price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.18 | $1.46 | 0% | Neutral | |
| $0.7689 | $1.06 | $1.58 | -10% | Neutral | |
| $0.7268 | $1.06 | $1.69 | -9% | Neutral | |
| $0.9206 | $1.42 | $2.37 | +21% | Bullish | |
| $1.01 | $1.63 | $2.84 | +39% | Bullish | |
| $0.8946 | $1.51 | $2.72 | +29% | Bullish | |
| $0.7933 | $1.40 | $2.59 | +19% | Neutral | |
| $0.682 | $1.25 | $2.38 | +7% | Neutral | |
| $0.7062 | $1.35 | $2.63 | +15% | Neutral | |
| $0.8063 | $1.60 | $3.20 | +36% | Bullish | |
| $0.828 | $1.84 | $4.04 | +57% | Bullish | |
| $1.82 | $4.04 | $9.30 | +244% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.17 | $1.18 | $1.47 | +0.00% |
| August 2026 | $0.9477 | $1.15 | $1.45 | -2.26% |
| September 2026 | $0.8771 | $1.08 | $1.39 | -6.14% |
| October 2026 | $0.9048 | $1.13 | $1.48 | +4.42% |
| November 2026 | $0.9257 | $1.16 | $1.55 | +3.38% |
| December 2026 | $0.8522 | $1.08 | $1.46 | -7.05% |
Click any year to see its month-by-month KALA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, KALA could reach as high as $1.46, with a base case around $1.18 and support toward $1.17 — roughly 0% from $1.18. Price action looks broadly range-bound.
Expect KALA to range from $0.7689 to $1.58 through 2027. The $1.06 average target implies a -10% move from current prices. That is -10% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The KALA price prediction for 2028 points to an average of $1.06 (low $0.7268, high $1.69) — a potential decline of -9% on today's $1.18. Price action looks broadly range-bound.
In 2029, KALA is projected to trade between $0.9206 and $2.37, averaging $1.42 — a potential gain of +21% from today's $1.18. That is up +33% on the projected 2028 average. Buyers look set to stay in control over this stretch.
KALA BIO, Inc.'s 2030 outlook centres on $1.63, within a $1.01 to $2.84 range. That is up +15% on the projected 2029 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2031, KALA could reach as high as $2.72, with a base case around $1.51 and support toward $0.8946 — roughly +29% from $1.18. Buyers look set to stay in control over this stretch.
Expect KALA to range from $0.7933 to $2.59 through 2032. The $1.40 average target implies a +19% move from current prices. That is -8% versus the projected 2031 average. Price action looks broadly range-bound.
The KALA price prediction for 2033 points to an average of $1.25 (low $0.682, high $2.38) — a potential gain of +7% on today's $1.18. A consolidation phase looks the most probable path here.
In 2034, KALA is projected to trade between $0.7062 and $2.63, averaging $1.35 — a potential gain of +15% from today's $1.18. That is up +8% on the projected 2033 average. Price action looks broadly range-bound.
KALA BIO, Inc.'s 2035 outlook centres on $1.60, within a $0.8063 to $3.20 range. That is up +19% on the projected 2034 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, KALA could reach as high as $4.04, with a base case around $1.84 and support toward $0.828 — roughly +57% from $1.18. Momentum favours further upside here.
Expect KALA to range from $1.82 to $9.30 through 2050. The $4.04 average target implies a +244% move from current prices. That is up +120% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KALA today (≈ 851.06383 KALA) could be worth
$3,441.91
+$2,441.91 (+244%) by 2050 · US Dollar
Based on the average projected KALA price of $4.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KALAwould be worth at today's price.
$1,000 invested in KALA on Jul 10, 2025 (≈ 2.898551 KALA) would be worth
$3.41
-$996.59 (-99.7%) today · 0.00× · US Dollar
Based on a KALA entry price of $345 vs. today's $1.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.68 | $699.4 | -30.1% |
| 1 month ago | $2.39 | $491.63 | -50.8% |
| 3 months ago | $10.15 | $115.76 | -88.4% |
| 6 months ago | $32 | $36.72 | -96.3% |
| 1 year ago | $345 | $3.41 | -99.7% |
| All time (5.0y) ago | $10,625 | $0.11 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KALA forecast.
Our base-case forecast reaches $2.40 around 2050.
Implied market cap at $2.40: $44.62M
The long-range forecast maps a bullish arc beginning in the late 2020s. For 2029, the average price is $1.42 with a max of $2.37 and a min of $0.9206, yielding a 20.9% ROI and a bullish signal. In 2030, the average rises to $1.63 with a max of $2.84 and a min of $1.01, delivering a 39% ROI and a bullish outlook.
In 2031, the average is $1.51 (min $0.8946, max $2.72) with a 28.7% ROI and a bullish stance. The forecast suggests a broad set of movements through 2032–2034 with smaller gains (2032 avg $1.40, max $2.59, ROI 19.1; 2033 avg $1.25, max $2.38, ROI 6.6; 2034 avg $1.35, max $2.63, ROI 14.8), before turning more decisively bullish in 2035 (avg $1.60, max $3.20, min $0.8063, ROI 36.3).
The trajectory remains bullish into 2040 (avg $1.84, max $4.04, min $0.828, ROI 56.6) and culminates in 2050 (avg $4.04, max $9.30, min $1.82, ROI 244.2). These milestones reflect a sustained upward pathway but rely on outcomes that are uncertain and not guaranteed. Investors should consider the implied upside against the substantial variability shown in earlier years and the broader market environment.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.63, with a possible high of $2.84 and a low of $1.01. The projected ROI is 39%, and the sentiment is BULLISH. These are estimates, not guarantees.
Forecasts indicate positive momentum in 2029–2031 (e.g., 2029 avg $1.42, ROI 20.9%; 2030 avg $1.63, ROI 39%; 2031 avg $1.51, ROI 28.7%) and again in 2035/2040/2050. Earlier years show negativeROIs (e.g., 2027 -9.8% and 2028 -9.4%), so outcomes are uncertain and not guaranteed.
Yes, the forecast lists a max price of $9.30 for 2050, with an average of $4.04 in that year. This indicates potential upside under the stated forecast, but it is not a guaranteed outcome.
The current price is $1.18.
The 30-day range is $0.683 to $2.02.
KALA BIO, Inc. Community Discussion
0Share your KALA BIO, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.